Last reviewed · How we verify

NCT05472376

Real-Life Study in Diabetic Macular Edema

Completed Last updated 25 July 2022
What this trial tests

trial testing Retrospective study in Diabetic Macular Edema in 854 participants. Completed in 15 June 2022.

Timeline
29 November 2020
Primary endpoint
17 March 2022
15 June 2022

Quick facts

Lead sponsorKocaeli University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment854
Start date29 November 2020
Primary completion17 March 2022
Estimated completion15 June 2022
Sites10 locations across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kocaeli University

Who can join

Eligibility, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to evaluate the real-world outcomes of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment in diabetic macular edema (DME) patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1.
    Yayla U, Sevik MO, Karabaş VL, Şahin Ö, et al · · 2023 · cited 7× · PMID 38126607 · DOI 10.4274/tjo.galenos.2023.56249

Verify or expand the search:

Other trials of Retrospective study

Trials testing the same drug.

Other recruiting trials for Diabetic Macular Edema

Currently open trials in the same condition.

Other Kocaeli University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05472376.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing